WOOJUNG BIO, Inc. (KOSDAQ:215380)
South Korea · Delayed Price · Currency is KRW 2,450.00
-255.00 (-9.43%)
At close: Apr 2, 2026
WOOJUNG BIO Revenue
In the year 2025, WOOJUNG BIO had annual revenue of 37.59B KRW, down -12.99%. WOOJUNG BIO had revenue of 12.43B in the quarter ending December 31, 2025, with 3.88% growth.
Revenue
37.59B
Revenue Growth
-12.99%
P/S Ratio
1.15
Revenue / Employee
n/a
Employees
n/a
Market Cap
43.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 37.59B | -5.61B | -12.99% |
| Dec 31, 2024 | 43.20B | 4.58B | 11.87% |
| Dec 31, 2023 | 38.62B | -8.30B | -17.70% |
| Dec 31, 2022 | 46.92B | 15.68B | 50.20% |
| Dec 31, 2021 | 31.24B | -6.11B | -16.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HLB bioStep | 74.05B |
| C&R Research | 64.98B |
| DreamCIS | 62.06B |
| DT&CRO CO. | 44.36B |
| BioInfra | 23.15B |
| P&K Skin Research Center | 22.13B |
| Penetrium Bioscience | 9.74B |
| Curachem | 6.02B |